| Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator … JP Frias, MA Nauck, J Van, ME Kutner, X Cui, C Benson, S Urva, ... The Lancet 392 (10160), 2180-2193, 2018 | 663 | 2018 |
| Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial I Raz, PWF Wilson, K Strojek, I Kowalska, V Bozikov, AK Gitt, G Jermendy, ... Diabetes care 32 (3), 381-386, 2009 | 473 | 2009 |
| Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) M Nauck, RS Weinstock, GE Umpierrez, B Guerci, Z Skrivanek, Z Milicevic Diabetes care 37 (8), 2149-2158, 2014 | 345 | 2014 |
| Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, ... New England Journal of Medicine 389 (6), 514-526, 2023 | 312 | 2023 |
| Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label … L Blonde, J Jendle, J Gross, V Woo, H Jiang, JL Fahrbach, Z Milicevic The Lancet 385 (9982), 2057-2066, 2015 | 275 | 2015 |
| Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial B Ludvik, JP Frías, FJ Tinahones, J Wainstein, H Jiang, KE Robertson, ... The lancet Diabetes & endocrinology 6 (5), 370-381, 2018 | 253 | 2018 |
| Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes MK Thomas, A Nikooienejad, R Bray, X Cui, J Wilson, K Duffin, Z Milicevic, ... The Journal of Clinical Endocrinology & Metabolism 106 (2), 388-396, 2021 | 204 | 2021 |
| Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia Z Milicevic, I Raz, SD Beattie, BN Campaigne, S Sarwat, E Gromniak, ... Diabetes care 31 (Supplement_2), S155-S160, 2008 | 198 | 2008 |
| Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: a 12 … JP Frias, MA Nauck, J Van, C Benson, R Bray, X Cui, Z Milicevic, S Urva, ... Diabetes, Obesity and Metabolism 22 (6), 938-946, 2020 | 174 | 2020 |
| Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study RS Weinstock, B Guerci, G Umpierrez, MA Nauck, Z Skrivanek, Z Milicevic Diabetes, Obesity and Metabolism 17 (9), 849-858, 2015 | 159 | 2015 |
| Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with … P Pozzilli, P Norwood, E Jódar, MJ Davies, T Ivanyi, H Jiang, ... Diabetes, Obesity and Metabolism 19 (7), 1024-1031, 2017 | 148 | 2017 |
| Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised … T Heise, A Mari, JH DeVries, S Urva, J Li, EJ Pratt, T Coskun, MK Thomas, ... The Lancet Diabetes & Endocrinology 10 (6), 418-429, 2022 | 147 | 2022 |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 … J Rosenstock, J Frias, AM Jastreboff, Y Du, J Lou, S Gurbuz, MK Thomas, ... The Lancet 402 (10401), 529-544, 2023 | 139 | 2023 |
| Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11) JP Frias, E Bonora, L Nevarez Ruiz, YG Li, Z Yu, Z Milicevic, R Malik, ... Diabetes Care 44 (3), 765-773, 2021 | 137 | 2021 |
| LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept T Coskun, S Urva, WC Roell, H Qu, C Loghin, JS Moyers, LS O’Farrell, ... Cell metabolism 34 (9), 1234-1247. e9, 2022 | 127 | 2022 |
| Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy I Mišur, K Žarković, A Barada, L Batelja, Z Miličević, Z Turk Acta diabetologica 41, 158-166, 2004 | 116 | 2004 |
| Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double … G Grunberger, A Chang, G Garcia Soria, FT Botros, R Bsharat, Z Milicevic Diabetic medicine 29 (10), 1260-1267, 2012 | 115 | 2012 |
| LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised … S Urva, T Coskun, MT Loh, Y Du, MK Thomas, S Gurbuz, A Haupt, ... The Lancet 400 (10366), 1869-1881, 2022 | 108 | 2022 |
| A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan V Mattoo, Z Milicevic, JK Malone, M Schwarzenhofer, A Ekangaki, ... Diabetes research and clinical practice 59 (2), 137-143, 2003 | 108 | 2003 |
| Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia I Raz, A Ceriello, PW Wilson, C Battioui, EW Su, L Kerr, CA Jones, ... Diabetes care 34 (7), 1511-1513, 2011 | 103 | 2011 |
